Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2020, with a specific reporting date of February 19, 2020. The document serves as a transaction notification regarding the granting of awards under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan (DABP) to Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data presented relates to the valuation of specific equity awards granted on February 14, 2020:
- Ordinary Shares Price: GBP 16.814 per share.
- American Depositary Shares (ADS) Price: USD 43.78 per ADS.
- Total Awards Granted: The filing details individual share/ADS volumes for 13 executives, totaling 192,341 Ordinary Shares and 41,884 ADSs.
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It strictly documents the execution of a standard compensation plan provision. The text notes that with effect from 2018, DABP Matching Awards are no longer granted, but this is a historical policy change, not a new development in this reporting period.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose new risks or contingencies. The document confirms that Executive Directors are required to defer 50% of their bonus into shares/ADSs for three years, while other Corporate Executive Team members must defer 25%. Awards were granted as restricted awards over ADSs for US participants and nil-cost options over Ordinary Shares for others.
Investor Verification Checklist
- Verify the total number of shares and ADSs granted to ensure alignment with the company's disclosed compensation policies.
- Confirm the share price used for the awards (GBP 16.814 and USD 43.78) against market prices on February 14, 2020.
- Review the DABP rules to confirm the deferral periods (three years) and vesting conditions for the listed executives.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F or quarterly reports for those metrics.